Seller record · Telehealth service

TeleWellnessMD

By Peptide Alliance, Editorial publisherRecorded October 2026 · Standard v1.1 · How checks are performed

Fails 1 of 8 criteria. S5, analytical documentation: The prescription catalog and FDA disclosure publish no certificate of analysis or lot document.

At a glance

TeleWellnessMDTelehealth service

5/8criteria passed

Price: Printed on its own pages before sign-up
Sells: semaglutide, oral semaglutide, tirzepatide, and 1 more
FDA letters: None on file

Visit TeleWellnessMD See all eight dispositions

Telehealth service. Passes 5 of 8 criteria. 2 not verified, counting neither way. Recorded against Standard v1.1.

A telehealth service with a public prescription catalog covering compounded GLP-1 treatments and other wellness therapies, dispensed after a licensed provider consultation.

Operating entity TeleWellnessMD, LLC

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	TeleWellnessMD's fdadisclosure page
S2	Prescription gating	NOT VERIFIED	TeleWellnessMD's fdadisclosure page; TeleWellnessMD's terms of use page
S3	Pharmacy identification	NOT VERIFIED	TeleWellnessMD's terms of use page; TeleWellnessMD's FAQ
S4	Compounding disclosure	PASS	TeleWellnessMD's fdadisclosure page
S5	Analytical documentation	FAIL	TeleWellnessMD's GLP-1 therapies page; TeleWellnessMD's fdadisclosure page
S6	Business address	PASS	TeleWellnessMD's fdadisclosure page; TeleWellnessMD's refundreturnpolicy page
S7	Price disclosure	PASS	TeleWellnessMD's GLP-1 therapies page
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSThe FDA disclosure states that prescription medications are provided only after a licensed healthcare provider conducts a telehealth consultation and determines medical necessity.Source: TeleWellnessMD's fdadisclosure page.

S2NOT VERIFIEDThe payment-sequence question did not resolve from the published material. The published policy requires consultation before medication is provided, but does not establish whether payment is collected before that evaluation. The check is open.Source: TeleWellnessMD's fdadisclosure page; TeleWellnessMD's terms of use page.

S3NOT VERIFIEDThe dispensing-pharmacy question did not resolve from the published material. The terms allow a partner pharmacy or a pharmacy selected by the patient. The available FAQ text does not establish a named dispensing facility. The check is open.Source: TeleWellnessMD's terms of use page; TeleWellnessMD's FAQ.

S4PASSThe FDA disclosure states that compounded drugs are not FDA-approved or evaluated for safety, effectiveness or quality and are prescribed for individual patients.Source: TeleWellnessMD's fdadisclosure page.

S5FAILThe prescription catalog and FDA disclosure publish no certificate of analysis or lot document.Source: TeleWellnessMD's GLP-1 therapies page; TeleWellnessMD's fdadisclosure page.

S6PASSThe FDA disclosure and returns policy list 2744 Summerdale Dr, Clearwater, FL 33761 as the company correspondence address.Source: TeleWellnessMD's fdadisclosure page; TeleWellnessMD's refundreturnpolicy page.

S7PASSThe GLP-1 catalog lists semaglutide at $199.95, oral semaglutide at $299.95, tirzepatide at $279.95 and oral tirzepatide at $399.95. The catalog does not establish a monthly supply duration for these figures.Source: TeleWellnessMD's GLP-1 therapies page.

S8PASSNo FDA warning letter names TeleWellnessMD or TeleWellnessMD LLC, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: semaglutide, oral semaglutide, tirzepatide, oral tirzepatide.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide

Visit TeleWellnessMD

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.